Blog | Page 2 of 21 | Oncotarget

Oncotarget News

Behind the Study: ER Expression Multiclonality in DCIS: Clinical & Future Insights

August 29, 2023

Dr. Mangesh A. Thorat from Guy’s Hospital in London, Queen Mary University of London, and King’s College London, describes a recent editorial he authored that was published by... read more

Oncotarget

A Macrophage is a Macrophage is a Macrophage—in Metastasis

August 23, 2023

We hope that these results will inform future attempts at anti-macrophage therapy and lead to better outcomes for patients in the not-too-distant future.” BUFFALO, NY- August 23, 2023 – A... read more

Oncotarget

Aggressive Luminal Breast Cancer: Are Cis-Spliced Fusion Proteins Pathological?

August 21, 2023

Our findings may provide a useful therapeutic approach for treating breast cancer patients who may suffer from early relapse and intrinsic resistance.” BUFFALO, NY- August 21, 2023 – A new... read more

Figure 1: Glutamine metabolism effect in tumor microenvironment cells.

Oncotarget

Inhibiting Glutamine Metabolism Impacts Tumor Cells or the Microenvironment?

August 16, 2023

These new findings evidence the necessity of more research in Gln metabolism to define the best therapeutic strategies for cancer patients.” BUFFALO, NY- August 16, 2023 – A new editorial... read more

Figure 1: Tumor intrinsic and extrinsic factors in the periphery that can serve as proxies of tumor burden. Peripheral surrogates

Oncotarget

Peripheral Surrogates of Tumor Burden to Guide Therapeutic Strategies for HPV-Associated Malignancies

August 14, 2023

We discuss existing clinical data on these surrogates of tumor burden and their potential in evaluating efficacy of immunotherapy in HPV-associated malignancies.” BUFFALO, NY- August 14, 2023 – A new... read more

Figure 1: PET scan at screening (A), 5 months (B) and 8 months on treatment (C). CDK9 INHIBITORS

Oncotarget

CDK9 Inhibitors: A Promising Combination Partner in Treating Hematological Malignancies

August 9, 2023

CDK9 inhibitors could play a role in future treatments of hematological diseases and could be a great ally when combined with other therapeutic approaches.” BUFFALO, NY- August 9, 2023 –... read more

Figure 1: Scheme of mechanisms of AGO2 (de)regulation and its (novel) functions in T-PLL.

Oncotarget

AGO2 in T-prolymphocytic Leukemia (T-PLL)

August 7, 2023

For the first time, descriptive and mechanistic data implicated the involvement of molecules of the RNA interference (RNAi) machinery in T-PLL’s leukemogenesis [...]” BUFFALO, NY- August 7, 2023 – A... read more

Figure 2: Mechanism of radiation resistance in H3K27me3-deficient medulloblastoma.

Oncotarget

Epigenetically Guided Cancer Therapy: Targeting H3K27me3 Loss in Pediatric Brain Tumors

August 2, 2023

our discovery of H3K27me3 as an epigenetic marker of radiation resistance in medulloblastoma has a potential to open new therapeutic avenues [...]”BUFFALO, NY- August 2, 2023 – A new editorial paper... read more

Figure 1: Multi-clonal ER expression in DCIS.

Oncotarget

Multiclonality of Estrogen Receptor Expression in Ductal Carcinoma in Situ (DCIS)

August 1, 2023

We have discussed in detail the clinical implications of ER in avoiding overtreatment and undertreatment in DCIS.”BUFFALO, NY- August 1, 2023 – A new editorial paper was published in Oncotarget's... read more

Figure 2: ShRNAs targeting KIAA0930 decrease KIAA0930 mRNA expression and suppress muscle atrophy in PANC-1 cells in vitro.

Oncotarget

KIAA0930: A Cachexic Phenotype Inducer in Cancer Cells

July 26, 2023

We believe that KIAA0930 would be a novel cachexia therapeutic target.”BUFFALO, NY- July 26, 2023 – A new research paper was published in Oncotarget's Volume 14 on July 20, 2023,... read more